iCellate Medical closes 15 million SEK second round of funding


iCellate, a privately held Swedish Medtech company, is very happy to announce the closing of the 15 million SEK second round of funding. iCellate is active in the field of cancer management and uses a simple blood test to detect circulating tumor cells (CTC) in the bloodstream, which is the mechanism that cancer spreads from a primary tumor to form metastases. 

Pelle Redare, CEO, comments “With this funding we secure the upcoming commercialization phase, which includes new facilities with a new lab, strengthening of the IP-portfolio and further development of our product offering”.